FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of AgeBusiness Wire • 09/25/20
Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR ModulatorsBusiness Wire • 09/24/20
Vertex Pharmaceuticals (VRTX) Stock Moves -0.52%: What You Should KnowZacks Investment Research • 09/21/20
Beyond Coronavirus: Moderna Teams Up With Vertex on Cystic Fibrosis TherapyThe Motley Fool • 09/18/20
Stock Market Crash 2.0: Here Are 3 Stocks You'll Absolutely, Positively Want to BuyThe Motley Fool • 09/17/20
Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene EditingBusiness Wire • 09/16/20
Vertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People with One Copy of the F508del MutationBusiness Wire • 09/14/20
3 Incredibly Strong Stocks to Buy That Should Thrive Even If the Stock Market Crashes AgainThe Motley Fool • 09/11/20
Vertex Pharmaceuticals Reports Positive Phase 3 Results in Children for Blockbuster CF DrugThe Motley Fool • 09/10/20
Vertex Announces Positive Phase 3 Study for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children Ages 6-11 Years With Cystic Fibrosis to Support Submissions for Global Regulatory ApprovalsBusiness Wire • 09/10/20